A synthetic peptide analog of human growth hormone's lipolytic domain that promotes fat loss by stimulating lipolysis and inhibiting lipogenesis without growth effects.
Heffernan. M M; Summers. R J RJ; Thorburn. A A; Ogru. E E; Gianello. R R; Jiang. W J WJ; Ng. F M FM
In obese mice, both human growth hormone and its fragment AOD9604 helped them lose weight and body fat after two weeks of daily injections. They also boosted the amount of a fat‑burning receptor (beta‑3‑adrenergic receptor) in the animals' fat cells. When that receptor was genetically removed, the long‑term treatment stopped working, but a single dose of AOD9604 still raised energy use and fat burning, meaning it can act through other pathways too.
The article reviews the current medical options for treating obesity, highlighting that diet and lifestyle alone often give only modest weight loss. It lists FDA‑approved drugs and newer compounds, including the peptide AOD9604, that work by reducing appetite or altering how the body stores fat.
Ng. F M FM; Sun. J J; Sharma. L L; Libinaka. R R; Jiang. W J WJ; Gianello. R R
In a study with obese rats, an oral peptide called AOD9604 (a tiny piece of human growth hormone) cut weight gain by more than half over three weeks, boosted fat‑burning activity in fat tissue, and didn’t mess up the animals’ insulin sensitivity. The researchers think this could become a safe, pill‑type weight‑loss aid, but it’s still only tested in animals.
The abstract reviews many new weight‑loss approaches, noting that the peptide AOD9604 is being tested in clinical trials for its ability to improve fat tissue function and fatty‑acid metabolism, but it doesn’t give any concrete results or dosing info.
The article is a review of how labs look for new performance‑enhancing substances, including the peptide AOD‑9604, in athletes' blood or urine. It talks about the lab techniques needed to spot these tiny molecules, but it doesn't give any advice on how to use the peptide or its benefits.
Thevis. Mario M; Thomas. Andreas A; Schänzer. Wilhelm W
The article reviews how anti‑doping labs hunt down peptide drugs such as AOD‑9604. It explains that modern techniques like mass‑spectrometry, chromatography and immuno‑tests can spot these tiny molecules in tiny blood or urine samples, but there’s still a gap between what’s technically possible and what’s done every day.
In a rabbit knee‑arthritis model, injecting the peptide AOD9604 directly into the joint helped the cartilage heal, and the benefit was even bigger when it was mixed with hyaluronic acid. The combo also made the rabbits limp for a shorter time than any single treatment or placebo.
The paper is a broad review of weight‑loss drugs and mentions AOD9604, a fragment of human growth hormone, as one of the experimental compounds being studied for obesity, but it gives no data on how well it works, how to dose it, or any safety information.
The article reviews several anti‑obesity drugs that are still being tested, including AOD‑9604, a fragment of human growth hormone that is said to help break down fat. It notes that most of these compounds are still early in trials, with only rimonabant having finished Phase III. No new data on dosing or effectiveness of AOD‑9604 are provided.
Thomas. Andreas A; Görgens. Christian C; Guddat. Sven S; Thieme. Detlef D; Dellanna. Frank F; S...
The paper describes a new lab test that can spot tiny amounts of many performance‑enhancing peptides, including AOD‑9604, in urine. It shows the test is very sensitive, works over a useful range, and that the peptides stay stable when urine is kept at –20 °C.
The abstract is just a list of many drugs, including AOD‑9604, that appear in a clinical‑trial database guide. It doesn’t give any results, dosages, or safety info for AOD‑9604, so there’s nothing concrete you can apply right now.
AOD-9604 is a peptide that Metabolic is testing as a possible obesity treatment, and by early 2002 it had entered Phase IIa clinical trials. No results, dosing info, or safety data are provided in the abstract.